Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prior Breast Cancer and Survival in Patients with UPSC

Gynecol Oncol; ePub 2017 Jan 3; Pierce, Stine, et al

Publish date:: February 6, 2017

In women diagnosed with uterine papillary serous carcinoma (UPSC) and with a history of breast cancer (UPSCBR+), or with UPSC and without a history of breast cancer (UPSCBR-), a recent study found no difference in progression-free survival (PFS) and overall survival (OS). Furthermore, prior tamoxifen exposure was not associated with survival outcomes in patients with UPSC and breast cancer. Researchers also found:

Among 323 patients with UPSC, 46 (14%) were UPSCBR+; 15 (33%) of these had a history of tamoxifen use.
UPSCBR+ women demonstrated no significant differences in PFS or OS compared to UPSCBR- women, even after controlling for age.
There was no difference in PFS or OS with or without tamoxifen exposure within the UPSCBR+ cohort.

Citation:

Pierce SR, Stine JE, Gehrig PA, et al. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. [Published online ahead of print January 3, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2016.12.024.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Pregnancy after breast cancer is rockier but doesn't increase recurrence risk,

Breast surgery may be a gateway to addictive medication use,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,